Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases
Mormino EC, Toueg TN, Azevedo C, Castillo JB, Guo W, Nadiadwala A, Corso NK, Hall JN, Fan A, Trelle AN, Harrison MB, Hunt MP, Sha SJ, Deutsch G, James M, Fredericks CA, Koran ME, Zeineh M, Poston K, Greicius MD, Khalighi M, Davidzon GA, Shen B, Zaharchuk G, Wagner AD, Chin FT. Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 48: 2233-2244. PMID: 32572562, PMCID: PMC7755737, DOI: 10.1007/s00259-020-04923-7.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAgingAlzheimer DiseaseAmyloid beta-PeptidesBrainCarbolinesHumansMiddle AgedNeurodegenerative DiseasesPositron-Emission TomographyTau ProteinsConceptsStandardized uptake value ratioAlzheimer's diseaseHealthy controlsCourse of ADSemantic variant primary progressive aphasiaVariant primary progressive aphasiaNeurofibrillary tangle pathologyOlder healthy controlsUptake value ratioPrimary progressive aphasiaAnterior temporal poleMedial temporal lobeNovel PET ligandMethodsForty-nine participantsTangle pathologyTau-PETSvPPA patientsFocal uptakeEarly diagnosisSubtle elevationRobust elevationTemporal lobeHC groupProgressive aphasiaPET ligand